Urinary excretion of neutrophil gelatinase-associated lipocalin in diabetic rats

Oxidative Medicine and Cellular Longevity

Volumn 2014, Issue , 2014, Pages

  Arellano Buendía, Abraham Said ^a   García Arroyo, Fernando Enrique ^a   Cristóbal García, Magdalena ^a   Loredo Mendoza, María Lilia ^b   Tapia Rodríguez, Edilia ^a   Sánchez Lozada, Laura Gabriela ^a   Osorio Alonso, Horacio ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b UNIVERSIDAD PANAMERICANA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYMES; OXIDATIVE STRESS; OXYGEN; PROTEINS; RATS;

4-HYDROXY-NONENAL; DIABETIC NEPHROPATHY; GLOMERULAR FILTRATION RATE; GLUTATHIONE PEROXIDASE; NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN; STREPTOZOTOCIN ADMINISTRATION; SUPEROXIDE DISMUTASES; URINARY EXCRETION;

PHYSIOLOGY;

3 NITROTYROSINE; 4 HYDROXYNONENAL; CATALASE; CREATININE; GLUTATHIONE PEROXIDASE; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN; STREPTOZOCIN; SUPEROXIDE DISMUTASE; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; LIPOCALIN; NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN PROTEIN, RAT; ONCOPROTEIN; REACTIVE OXYGEN METABOLITE;

ALBUMINURIA; ARTICLE; CREATININE CLEARANCE; DIABETOGENESIS; DIURESIS; ENZYME ACTIVITY; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; OXIDATIVE STRESS; PROTEINURIA; QUANTITATIVE ANALYSIS; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TUBULAR DYSFUNCTION; URINARY EXCRETION; ANIMAL; DIABETIC NEPHROPATHY; EXPERIMENTAL DIABETES MELLITUS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; RAT; URINE; WISTAR RAT;

RATTUS;

ACUTE-PHASE PROTEINS; ANIMALS; BIOLOGICAL MARKERS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; LIPOCALINS; MALE; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES;

EID: 84927719110     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2014/961326     Document Type: Article

References (37)

1. "Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group," Kidney International, vol. 47, no. 6, pp. 1703-1720, 1995.
2. H. J. Bangstad, R. Sterby, K. Dahl-Jørgensen, K. J. Berg, A. Hartmann, and K. F. Hanssen, "Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy," Diabetologia, vol. 37, no. 5, pp. 483-490, 1994.
3. H. Osorio, I. Coronel, A. Arellano et al., "Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats," OxidativeMedicine and Cellular Longevity, vol. 2012, Article ID 542042, 7 pages, 2012.
4. H. Ha and H. B. Lee, "Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney," Nephrology, vol. 10, supplement 2, pp. S7-S10, 2005.
5. M. Von Eynatten, M. Baumann,U.Heemann et al., "Urinary LFABP and anaemia: Distinct roles of urinary markers in type 2 diabetes," European Journal of Clinical Investigation, vol. 40, no. 2, pp. 95-102, 2010.
6. K. Damman, D. J. Van Veldhuisen, G. Navis et al., "Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate," Heart, vol. 96, no. 16, pp. 1297-1302, 2010.
7. W. Fu, S. Xiong, Y. Fang et al., "Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: A cross-sectional study," Endocrine, vol. 41, no. 1, pp. 82-88, 2012.
8. L. Kjeldsen, A. H. Johnsen, H. Sengelov, and N. Borregaard, "Isolation and primary structure ofNGAL, a novel protein associated with human neutrophil gelatinase," Journal of Biological Chemistry, vol. 268, no. 14, pp. 10425-10432, 1993.
9. J. B. Cowland and N. Borregaard, "Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans," Genomics, vol. 45, no. 1, pp. 17-23, 1997.
10. J.Mishra, K. Mori, Q.Ma, C. Kelly, J. Barasch, and P. Devarajan, "Neutrophil gelatinase-associated lipocalin: A novel early urinary biomarker for cisplatin nephrotoxicity," The American Journal of Nephrology, vol. 24, no. 3, pp. 307-315, 2004.
11. J. Mishra, C. Dent, R. Tarabishi et al., "Neutrophil gelatinaseassociated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery," The Lancet, vol. 365, no. 9466, pp. 1231-1238, 2005.
12. M. M. Mitsnefes, T. S. Kathman, J. Mishra et al., "Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease," Pediatric Nephrology, vol. 22, no. 1, pp. 101-108, 2007.
13. D. Gérard-Monnier, I. Erdelmeier, K. Régnard, N. Moze-Henry, J. Yadan, and J. Chaudìere, "Reactions of 1-methyl-2-phenylindole with malondialdehyde and 4-hydroxyalkenals: Analytical applications to a colorimetric assay of lipid peroxidation," Chemical Research in Toxicology, vol. 11, no. 10, pp. 1176-1183, 1998.
14. I. Erdelmeier,D.Gérard-Monnier, J. C. Yadan, and J. Chaudìere, "Reactions of N-methyl-2-phenylindole with malondialdehyde and 4-hydroxyalkenals.Mechanistic aspects of the colorimetric assay of lipid peroxidation," Chemical Research in Toxicology, vol. 11, no. 10, pp. 1184-1194, 1998.
15. R. L. Levine, D. Garland, C. N. Oliver et al., "Determination of carbonyl content in oxidatively modified proteins," Methods in Enzymology, vol. 186, pp. 464-478, 1990.
16. H.Osorio, R. Bautista,A.Rios, M. Franco, J. Santamariá, and B. Escalante, "Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats," Diabetes Research and Clinical Practice, vol. 86, no. 3, pp. e46-e49, 2009.
17. J. Skrha, J. Perusicová, P. Stolba, V. Stibor, and J. Páv, "Comparison of N-acetyl-glucosaminidase and albuminuria with clinical finding of microangiopathy in type I diabetes mellitus," Clinica Chimica Acta, vol. 166, no. 2-3, pp. 135-141, 1987.
18. J. M.Wellwood, R. G. Price, B. G. Ellis, and A. E.Thompson, "A note on the practical aspects of the assay of N-acetyl-glucosaminidase in human urine," Clinica Chimica Acta, vol. 69, no. 1, pp. 85-91, 1976.
19. A. Bohle, M.Wehrmann,O. Bogenschutz, C. Batz, C. A.Muller, and G. A. Muller, "The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis," Pathology Research and Practice, vol. 187, no. 2-3, pp. 251-259, 1991.
20. K. Jung, M. Pergande, E. Schimke, K. P. Ratzmann, and A. Ilius, "Urinary enzymes and low-molecular-mass proteins as indicators of diabetic nephropathy," Clinical Chemistry, vol. 34, no. 3, pp. 544-547, 1988.
21. R. C. Blantz and P. Singh, "Glomerular and tubular function in the diabetic kidney," Advances in Chronic Kidney Disease, vol. 21, no. 3, pp. 297-303, 2014.
22. T. Kuwabara, K. Mori, M. Mukoyama et al., "Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons," Kidney International, vol. 75, no. 3, pp. 285-294, 2009.
23. K. Horie, T. Miyata, K. Maeda et al., "Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy," Journal of Clinical Investigation, vol. 100, no. 12, pp. 2995-3004, 1997.
24. H. Ha, C. Kim, Y. Son, M. H. Chung, and K. H. Kim, "DNA damage in the kidneys of diabetic rats exhibiting microalbuminuria," Free Radical Biology and Medicine, vol. 16, no. 2, pp. 271-274, 1994.
25. C. Sato-Horiguchi, D. Ogawa, J. Wada et al., "Telmisartan attenuates diabetic nephropathy by suppressing oxidative stress in db/db mice," Nephron: Experimental Nephrology, vol. 121, no. 3-4, pp. e97-e108, 2013.
26. M. Brownlee, "The pathobiology of diabetic complications: A unifying mechanism," Diabetes, vol. 54, no. 6, pp. 1615-1625, 2005.
27. E. Tapia, M. Franco, L. G. Sánchez-Lozada et al., "Mycophenolate mofetil prevents arteriolopathy and renal injury in subtotal ablation despite persistent hypertension," Kidney International, vol. 63, no. 3, pp. 994-1002, 2003.
28. R. L. Rouse, S. R. Stewart, K. L. Thompson, and J. Zhang, "Kidney injury biomarkers in hypertensive, diabetic, and nephropathy ratmodels treated with contrast media," Toxicologic Pathology, vol. 41, no. 4, pp. 662-680, 2013.
29. A. A. Al-Refai, S. I. Tayel, A. Ragheb, A. G.Dala, and A. Zahran, "Urinary neutrophil Gelatinase associated lipocalin as a marker of tubular damage in type 2 diabetic patients with and without albuminuria," Open Journal of Nephrology, vol. 4, pp. 37-46, 2014.
30. H. S. Assal, S. Tawfeek, E. A. Rasheed, D. El-Lebedy, and E. H. Thabet, "Serum cystatin C and tubular urinary enzymes as biomarkers of renal dysfunction in type 2 diabetes mellitus," Clinical Medicine Insights: Endocrinology and Diabetes, vol. 6, pp. 7-13, 2013.
31. S. Uslu, B. Efe, O. Alataş et al., "Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in diabetic patients," Journal of Nephrology, vol. 18, no. 5, pp. 559-567, 2005.
32. X. Yan,M. Sano, L. Lu et al., "Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus," Cardiovascular Diabetology, vol. 9, article 70, p. 8, 2010.
33. J. Lorenzen, R. Shah, A. Biser et al., "The role of osteopontin in the development of albuminuria," Journal of the American Society of Nephrology, vol. 19, no. 5, pp. 884-890, 2008.
34. H. Yamaguchi, M. Igarashi, A. Hirata et al., "Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients," Endocrine Journal, vol. 51, no. 5, pp. 499-504, 2004.
35. J. W. Fischer, C. Tschöpe, A. Reinecke, C. M. Giachelli, and T. Unger, "Upregulation of osteopontin expression in renal cortex of streptozotocin-induced diabetic rats is mediated by bradykinin," Diabetes, vol. 47, no. 9, pp. 1512-1518, 1998.
36. M. A. Fathy, M. M. Elkady, H. A. Fathy, S. A. Awad, and A. A. Elmenshawy, "Estimation of renal tubular markers for predicting early stage diabetic nephropathy in Egyptian children with type I diabetesmellitus," Research Journal ofMedicine&Medical Sciences, vol. 4, no. 2, p. 207, 2009.
37. A. Mohammadi-Karakani, S. Asgharzadeh-Haghighi, M. Ghazi-Khansari, and R. Hosseini, "Determination of urinary enzymes as a marker of early renal damage in diabetic patients," Journal of Clinical Laboratory Analysis, vol. 21, no. 6, pp. 413-417, 2007.